The RR (fixed effect) to develop grade 3–4 QTc prolongation was 7.51 (95% CI, 2.16–26.15; p = 0.002, Figure 3B) in NSCLC patients received ALK-TKIs in comparison with controls. The gene discussed is ALK; the disease is non-small cell lung carcinoma.